MedTrace Logo

Open-Label Extension of LOCKCYST Trial

NCT00771888 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2008-11-13

No results posted yet for this study

Summary

Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated polycystic livers and no other therapeutic options were available.

Patients who participated in LOCKCYST trial are able to benefit from active treatment. Participants will be actively treated for 24 weeks.

Conditions

  • Polycystic Liver Disease
  • Hepatomegaly
  • Liver Diseases
  • Polycystic Kidney
  • Autosomal Dominant

Interventions

DRUG

lanreotide

lanreotide

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Joost PH Drenth, PhD · Radboud University Nijmegen Medical Center

  • Frederik Nevens, MD, PhD · University Hospital Gasthuisberg, University of Leuven

  • Loes van Keimpema, MSc · Radboud University Nijmegen Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-10-31
Completion
2009-08-31

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771888 on ClinicalTrials.gov